ABSTRACT
Desde que Mitchel en 1864 la denominara causalgia y en1909 Paul Sudeck la bautizara, a día de hoy continúa siendoun reto para la clínica médica. Su inespecificidad diagnóstica,añadida al gran número de factores precipitantes y a suetiopatogenia no claramente esclarecida y de terapéuticacontrovertida hacen de esta enfermedad un cuadro clínicocomplejo tanto para el paciente como para quien lo asiste.Llegar a un diagnóstico precoz es el eje principal del tratamientodel síndrome de Sudeck.Puede afectar a cualquier edad y tanto a hombres como amujeres, aunque estadísticamente es más frecuente en mujeresjóvenes.La incidencia de la enfermedad es variable, oscilando entreel 2 y el 25% de la población, aunque en nuestro país noconocemos cifras. Indudablemente es una entidad que pasahabitualmente desapercibida para nuestra comunidad médicaen general (AU)
Since Mitchell coined the term causalgia in 1864 and PaulSudeck baptized it in 1909, this disease continues to be achallenge for the medical clinician. Its non-specific diagnosisas well as its large number of precipitating factors, this alladded to its etiopathogenesis that cannot be clearly clarifiedand its controversial treatment, makes this disease a complexclinical picture for both the patient and treating clinician.Reaching an early diagnostic is fundamental in the treatmentof Sudecks syndrome. It can affect any age group andboth men as well as women, although it is more frequent inyoung women statistically.The incidence of the illness is variable, ranging from 2%to 25% of the population. Although there are no known valuesin our country, it is undoubtedly a condition that generallygoes unnoticed in our medical community (AU)
Subject(s)
Humans , Male , Female , Reflex Sympathetic Dystrophy/diagnosis , Signs and Symptoms , Reflex Sympathetic Dystrophy/etiology , Reflex Sympathetic Dystrophy/history , Reflex Sympathetic Dystrophy/therapy , Hydrotherapy/methods , Pain/drug therapyABSTRACT
The possible involvement of platelet-activating factor (PAF) in the pathogenesis of endotoxemia, was investigated by using a binding assay to patients' platelets, complemented with the extraction and chemical characterization of PAF obtained from patients' platelets. Platelets from 12 human volunteers had 281 +/- 63 freely accessible high affinity binding sites (PAF-receptors) per platelet; whereas this number was of 49 +/- 37 PAF-receptors per platelet, n = 14 samples, P less than 0.01, in a group of 13 patients with positive blood culture. A group of patients with respiratory or cardiovascular disturbances and negative blood culture had 253 +/- 74, accessible receptors per platelet (n = 19 samples from 16 patients, P less than 0.01 as compared to septic patients, which was not significantly different when compared to control individuals). Patients with sepsis possessed significant amounts of PAF associated to their platelets, whereas this mediator could not be isolated from platelets of patients with respiratory or cardiovascular disturbances and negative blood culture, nor from platelets of control individuals. PAF was also assayed in whole blood samples and found at high concentrations in sepsis patients. These data indicate that occupancy of PAF receptors in combination with high amounts of platelet-associated PAF, is a common finding in patients with sepsis.